Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma

  title={Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma},
  author={Corrado Pelaia and Giulia Pelaia and Claudia Crimi and Angelantonio Maglio and Luca Gallelli and Rosa Terracciano and Alessandro Vatrella},
  journal={International Journal of Molecular Sciences},
Thymic stromal lymphopoietin (TSLP) is an innate cytokine, belonging to the group of alarmins, which plays a key pathogenic role in asthma by acting as an upstream activator of cellular and molecular pathways leading to type 2 (T2-high) airway inflammation. Released from airway epithelial cells upon tissue damage induced by several noxious agents including allergens, viruses, bacteria, and airborne pollutants, TSLP activates dendritic cells and group 2 innate lymphoid cells involved in the… 

Figures from this paper

Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma
The fully human anti-TSLP monoclonal antibody tezepelumab has been evaluated in very promising randomized clinical trials and is likely to become, in the near future, valuable therapeutic options for the biological treatment of uncontrolled severe asthma.
Novel therapeutic approaches targeting endotypes of severe airway disease
This review provides the clinician with an overview of the prevalence and clinical impact of severe chronic upper and lower airways disease and suggests a novel therapeutic approach with biological agents with possible biomarkers.
Biologics in the Treatment of Severe Uncontrolled Asthma in Children
  • N. Syabbalo
  • Medicine, Biology
    Journal of Thoracic Disease and Cardiothoracic Surgery
  • 2021
Most of the children with asthma respond to low and medium inhaled corticosteroids, however a significant proportion still have severe asthma uncontrolled on the standard of care, and ILAs have been demonstrated to improve the health-related quality of life, and have steroid sparing effect.
Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis
A network meta-analysis to compare and rank the efficacy of five treatments for asthma in overall participants and in subgroups stratified by the thresholds of type 2 inflammatory biomarkers provided a basis for the development of treatment strategies for asthma.
Which Therapy for Non-Type(T)2/T2-Low Asthma
Clinical trials targeting biomarkers playing key roles in T3 and T1 immune pathways, alarmins, and molecules involved in neutrophil recruitment have provided conflicting results probably misleading in patients’ selection.
Hospital-initiated care bundle, post-hospitalization care, and outcomes in adults with asthma exacerbation.
Autophagy-Related Genes Are Involved in the Progression and Prognosis of Asthma and Regulate the Immune Microenvironment
Autophagy plays a crucial role in the diversity and complexity of the asthma immune microenvironment and has clinical value in treatment response and prognosis.


Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma
Systemic anti-TSLP monoclonal antibody therapy with tezepelumab has yielded positive results in clinical trials to date, reducing exacerbations and biomarkers of inflammation in patients across the spectrum of inflammatory endotypes.
Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma
An overview of the monoclonal antibody therapeutics market for severe uncontrolled asthma is provided, the underlying pathophysiology that drives TSLP is examined and the use of tezepelumab for the treatment of severe uncontrolled asthmatics is discussed.
Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
The effectiveness of benralizumab in improving severe eosinophilic asthma has been well-documented by many randomized controlled trials and is currently the only available biologic drug that specifically binds to the IL-5 receptor, thus preventing the interaction with its ligand and the consequent pro-inflammatory effects.
Function and mechanisms of TSLP/TSLPR complex in asthma and COPD
  • N. Redhu, A. Gounni
  • Biology, Medicine
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2012
Diverse mechanisms that mediate TSLP/TSLP receptor‐signalling network in chronic airway diseases are summarized to suggest a potential autocrine loop that may have a profound effect on local inflammatory response and airway remodelling.
TSLP Inhibitors for Asthma: Current Status and Future Prospects
Some critical aspects remain to be clarified before being able to define this approach as the one that will probably better help patients suffering from severe asthma because of its holistic effects, but new information suggests that targeting TSLP may be more likely to improve day-to-day asthma symptoms.
Anti-TSLP antibodies: Targeting a master regulator of type 2 immune responses.
Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2‐polarizing conditions
  • J. Tanaka, N. Watanabe, T. Chiba
  • Biology, Medicine
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2009
This work has shown that TSLP plays a critical role in the pathophysiology of human asthma, and its expression in the human asthmatic lung activates dendritic cells (DCs) to strongly induce proallergic T‐helper type 2 (Th2) cell responses.
Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
The unmet therapeutic need in severe asthma and the current treatment landscape is summarized, the rationale for targeting TSLP insevere asthma therapy is discussed, and tezepelumab is described, a first-in-class human monoclonal antibody that blocks the activity of TSLp.
TSLP: from allergy to cancer
This Review will highlight major recent advances in TSLP biology, along with results from emerging clinical trials of anti-TSLP agents used for the treatment of a variety of inflammatory conditions.
Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma
A fusion protein comprising a tandem of the TSLPR and IL-7Rα extracellular domains is introduced, which harnesses the mechanistic intricacies ofThe TSLP-driven receptor complex to manifest high antagonistic potency.